Medications for PCOS Symptoms: UK Guide

Medications for PCOS symptoms are chosen based on which features of polycystic ovary syndrome are most affecting an individual's health and quality of life. Because PCOS influences hormonal balance, menstrual regularity, fertility, and metabolic health, treatment is rarely one-size-fits-all. In the UK, options range from the combined oral contraceptive pill and metformin to ovulation-induction agents and anti-androgens. This article explains the main medicines used, how doctors select the right approach, what side effects to expect, and how lifestyle changes and NHS or private services fit into overall PCOS management.

Which medications are commonly used to treat PCOS symptoms in the UK?

The most commonly used medications for PCOS in the UK include the combined oral contraceptive pill, metformin, clomifene, letrozole, spironolactone, eflornithine cream, and GLP-1 receptor agonists, each targeting different aspects of the condition.

Several different medications are used to manage PCOS symptoms in the UK, chosen according to which features of the condition are most troublesome for each individual. Because polycystic ovary syndrome (PCOS) affects multiple body systems, including hormonal balance, menstrual regularity, fertility, and metabolic health, no single drug addresses every aspect of the condition.

The most widely used treatments include:

• Combined oral contraceptive pill (COCP): Regulates periods, reduces androgen-related symptoms such as acne and excess hair growth (hirsutism), and provides contraception. Pills containing a progestogen with anti-androgenic properties, such as drospirenone, may help with androgenic symptoms. Co-cyprindiol (cyproterone acetate combined with ethinylestradiol) is reserved for severe acne or hirsutism that has not responded to other treatments; it is not primarily a contraceptive, carries a higher risk of venous thromboembolism than most COCPs, and should only be used under appropriate medical supervision.^[1][3]

• Metformin: An insulin-sensitising medicine licensed for type 2 diabetes but used off-label in PCOS to improve insulin resistance, support menstrual regularity, and assist with weight management.^[2][3] NICE guidance acknowledges its role in PCOS management.

• Clomifene (clomiphene): An oral ovulation-induction agent used when fertility is the primary concern. It is prescribed under specialist supervision.

• Letrozole: An aromatase inhibitor used off-label for ovulation induction in PCOS. The 2023 International Evidence-Based PCOS Guideline (Monash/ESHRE/ASRM) recommends letrozole as a first-line option for anovulatory PCOS, and many UK specialist services use it in this way.^[11] It is prescribed under specialist supervision.

• Spironolactone: An anti-androgen sometimes used off-label to reduce hirsutism and acne when the COCP is not suitable or sufficient. Reliable contraception is essential during use (see side effects section).

• Eflornithine cream: A topical treatment licensed for facial hirsutism, used alongside other therapies.^[7]

• GLP-1 receptor agonists (such as liraglutide or semaglutide): Increasingly considered for women with PCOS and obesity, where weight management is a clinical priority, though their use in PCOS specifically remains largely off-label unless a separate licensed indication applies. These medicines are not recommended during pregnancy or breastfeeding, and women who could become pregnant should discuss contraception and pre-conception planning with their prescriber before starting treatment.

Treatment is always tailored to the individual, and a GP or gynaecologist will discuss the most appropriate options based on symptoms, reproductive plans, and overall health.

How do doctors decide which treatment is right for your PCOS?

Doctors base PCOS treatment decisions on reproductive goals, metabolic profile, predominant symptoms, and cardiovascular risk, using frameworks from NICE and the 2023 International Evidence-Based PCOS Guideline.

Doctors decide on PCOS treatment by first identifying which symptoms are causing the most significant impact on a person's health and quality of life, then matching those symptoms to the available evidence-based options. PCOS is a heterogeneous condition, meaning its presentation varies considerably between individuals, so a personalised approach is essential.

Diagnosis is typically based on the Rotterdam criteria, which require at least two of the following three features: irregular or absent periods, clinical or biochemical signs of androgen excess, and polycystic ovaries on ultrasound.^[11][3] Other conditions that can mimic PCOS are usually excluded before a diagnosis is confirmed. Typical exclusion tests include thyroid function (TSH), prolactin (to exclude hyperprolactinaemia), and 17-hydroxyprogesterone (to exclude non-classical congenital adrenal hyperplasia). Pelvic ultrasound findings should be interpreted with caution in adolescents and those within a few years of their first period, as polycystic ovarian morphology is common in this group and does not alone confirm PCOS.

Key factors that guide treatment decisions include:

• Reproductive goals: Women who are trying to conceive require ovulation-induction agents rather than hormonal contraceptives, which suppress ovulation.

• Metabolic profile: Elevated fasting glucose, insulin resistance, or a BMI above the healthy range may prompt the use of metformin or, in some cases, referral for weight management support.

• Predominant symptoms: Irregular periods alone may be managed with a COCP, whereas significant hirsutism or acne may warrant an anti-androgenic preparation or topical treatment.

• Cardiovascular and thrombotic risk: Some hormonal treatments carry a small increased risk of venous thromboembolism, so a personal and family history of clotting disorders influences prescribing.

• Comorbidities: Conditions such as type 2 diabetes, hypertension, or depression affect which medicines are safe and appropriate.

NICE clinical guideline NG88 (Fertility problems: assessment and treatment), NICE CKS on polycystic ovary syndrome, and the 2023 International Evidence-Based PCOS Guideline provide frameworks that UK clinicians use to structure these decisions.^[5] Initial assessment typically includes blood tests for androgens, fasting glucose or HbA1c, lipids, thyroid function, prolactin, and 17-hydroxyprogesterone, alongside a pelvic ultrasound where appropriate. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online consultations with prescriber review, and a prescriber may consider certain treatments where they are clinically appropriate following assessment.

What side effects should you watch for with PCOS medications?

Key side effects include venous thromboembolism risk with the COCP, gastrointestinal effects with metformin, ovarian hyperstimulation with clomifene or letrozole, and elevated potassium with spironolactone; severe abdominal pain on GLP-1 agonists warrants urgent review.

Each medication used for PCOS carries its own side effect profile, and being aware of these helps people make informed decisions and seek timely advice if problems arise. Side effects vary in frequency and severity, and many settle with time or dose adjustment.

Combined oral contraceptive pill: Common effects include nausea, breast tenderness, mood changes, and headaches. A small but real increased risk of venous thromboembolism (blood clots) exists, and this risk varies by progestogen type, oestrogen dose, and individual factors such as smoking, obesity, and immobility. Co-cyprindiol carries a higher VTE risk than most standard COCPs. Anyone experiencing sudden leg pain, breathlessness, or chest pain should contact 999 immediately, as these may indicate a clot.

Metformin: Gastrointestinal effects, including nausea, diarrhoea, and abdominal discomfort, are common, particularly when starting treatment. Taking metformin with food and using a slow-release formulation can reduce these effects. Lactic acidosis is a rare but serious complication, more likely in people with significant kidney impairment.

Clomifene: Hot flushes, mood changes, and visual disturbances can occur. If visual symptoms develop, clomifene should be stopped and urgent specialist review sought. There is a risk of ovarian hyperstimulation syndrome (OHSS) and multiple pregnancy, which is why it is used under specialist supervision.

Letrozole: When used off-label for ovulation induction, common effects include hot flushes, headaches, and fatigue. As with clomifene, there is a risk of OHSS and multiple pregnancy; specialist monitoring is required.

Spironolactone: Can cause dizziness, breast tenderness, and elevated potassium levels. It must not be used in pregnancy due to risk of feminisation of a male foetus, so reliable contraception is essential throughout treatment.^[3]

Eflornithine cream: Local skin reactions, including irritation, redness, and acne at the application site, are common. These are usually mild. The cream slows hair growth but does not remove existing hair.

GLP-1 receptor agonists: Nausea, vomiting, and reduced appetite are common, particularly during dose escalation. Acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome; anyone developing severe, persistent abdominal pain should seek urgent medical review via their GP or NHS 111. These medicines are not recommended during pregnancy or breastfeeding. Women who could become pregnant should use effective contraception and discuss pre-conception planning, including any required washout period, with their prescriber before stopping contraception.

Suspected side effects from any medicine can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Can lifestyle changes work alongside medication for PCOS?

Lifestyle changes, including a balanced diet, regular physical activity, and weight management, are a cornerstone of PCOS care and enhance the effectiveness of medications such as metformin.

Lifestyle changes are a cornerstone of PCOS management and work alongside medication rather than as an alternative to it. Evidence consistently shows that even modest improvements in diet, physical activity, and weight can meaningfully reduce insulin resistance, restore menstrual regularity, and improve androgen levels in women with PCOS.

Weight management: In women with PCOS and a BMI above the healthy range, a reduction of 5 to 10 per cent of body weight has been associated with improvements in menstrual frequency, ovulation rates, and androgen levels, as noted in the 2023 International Evidence-Based PCOS Guideline.^[11] This does not mean that weight loss is required for treatment to be effective, but it is a recognised modifier of outcomes.

Physical activity: Both aerobic exercise and resistance training improve insulin sensitivity. NHS guidance recommends at least 150 minutes of moderate-intensity activity per week for adults.^[6] Even breaking up prolonged sitting with short bouts of movement has measurable metabolic benefits.

Dietary approaches: No single diet is universally recommended for PCOS, but a balanced diet that limits refined carbohydrates and ultra-processed foods supports insulin regulation. A low glycaemic index (GI) approach may be particularly helpful for women with insulin resistance, and this is supported by the 2023 International Evidence-Based PCOS Guideline.^[11]

Psychological wellbeing: PCOS is associated with higher rates of anxiety and depression.^[10] Addressing mental health through talking therapies, peer support, or GP referral is an important part of holistic management.

Lifestyle interventions are most effective when supported by a multidisciplinary team, which may include a GP, dietitian, and physiotherapist. Medication such as metformin may enhance the effects of lifestyle change, particularly in women who find weight management difficult despite sustained effort.

How long does it take for PCOS medications to make a difference?

Menstrual regulation can improve within one to two cycles on the COCP, while hirsutism and acne may take six to twelve months to respond to anti-androgenic treatments.

The time it takes for PCOS medications to produce noticeable improvements varies considerably depending on the symptom being treated and the medicine used. Setting realistic expectations helps people stay engaged with treatment and avoid stopping prematurely.

Menstrual regulation: The combined oral contraceptive pill typically produces a regular withdrawal bleed within the first one to two cycles. Metformin may take three to six months to show a meaningful effect on cycle regularity, as it works by gradually improving insulin sensitivity rather than directly controlling the hormonal cycle.

Hirsutism and acne: These are among the slowest symptoms to respond because hair follicles and sebaceous glands have long biological cycles. Anti-androgenic treatments, whether via the COCP or spironolactone, generally require at least six months before a noticeable reduction in hair growth or acne is seen, with full benefit potentially taking twelve months or longer, as noted in the 2023 International Evidence-Based PCOS Guideline.^[8][11] Topical eflornithine cream can slow facial hair growth within eight weeks of regular use, though it does not remove existing hair.^[7]

Fertility: Ovulation induction with clomifene or letrozole (off-label) is typically assessed over three to six treatment cycles under specialist monitoring. If ovulation is not achieved or pregnancy does not result, specialist review is recommended to consider alternative or escalated therapies.

Metabolic markers: Improvements in fasting glucose, HbA1c, and lipid profiles with metformin or weight management interventions may be detectable within three months on blood tests, even before symptoms change noticeably.

Regular follow-up with a GP or specialist is important to assess response, adjust doses, and monitor for side effects. People should not stop medication without discussing it with their prescriber, as some symptoms can return quickly after discontinuation.

Where can you get PCOS treatment on the NHS or privately?

Most people with PCOS are initially assessed and treated by their GP on the NHS; referral to gynaecology or fertility services is available when needed, and private options offer faster specialist access.

PCOS treatment is available through NHS primary care, NHS specialist services, and private healthcare providers, with the most appropriate route depending on symptom complexity and local service availability. Most people with PCOS are initially assessed and managed by their GP, who can prescribe first-line treatments such as the combined oral contraceptive pill and metformin, arrange relevant blood tests and ultrasound, and refer to secondary care when needed.

NHS pathways:

• GP: The first point of contact for most people. GPs can diagnose PCOS, initiate treatment, and monitor response.

• Gynaecology or endocrinology: Referral is appropriate when symptoms are complex, fertility treatment is needed, or first-line management has not been effective.

• Fertility services: NHS-funded fertility treatment, including ovulation induction, is subject to local Integrated Care Board (ICB) commissioning decisions, which means eligibility criteria and the number of funded cycles vary by region.

• Dietitian and psychological support: Available via GP referral, though waiting times vary.

Private options: Private gynaecology and endocrinology consultations offer faster access to specialist assessment and a broader range of treatment options. Private prescriptions for PCOS medications are available but are not subsidised, so costs are higher than NHS prescription charges. It is important to ensure any private prescriber is registered with the General Medical Council (GMC), whose register can be verified at gmc-uk.org.

For people seeking online assessment, it is worth choosing a provider regulated by the GPhC (for pharmacies in Great Britain) or the Care Quality Commission (CQC) for online clinics in England. In Northern Ireland, pharmacy regulation is the responsibility of the Pharmaceutical Society of Northern Ireland (PSNI). Checking the relevant register helps confirm that a service meets required safety standards before sharing personal health information or beginning treatment.

Scientific References

1. Combined hormonal contraceptives and venous thromboembolism: review confirms risk is small.
2. Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6).
3. Polycystic ovary syndrome | Treatment summaries – BNF – NICE.
4. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases.
5. Fertility problems: assessment and treatment (NG257).
6. Physical activity guidelines for adults aged 19 to 64.
7. Topical eflornithine (Balfour JA et al., Drugs, 2001).
8. Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome. Journal of Women's Health, 2018.
9. Androgen excess in women: experience with over 1000 consecutive patients. Journal of Clinical Endocrinology and Metabolism, 2004.
10. Depressive and Anxiety Symptoms in Women with Polycystic Ovary Syndrome: A Meta-Analysis. Journal of Clinical Medicine, 2025.
11. 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (Monash University/ESHRE/ASRM).

Frequently Asked Questions